Suppr超能文献

采用快速酶联免疫吸附测定法测定胸腺球蛋白和抗淋巴细胞球蛋白排斥治疗后的致敏反应。美国胸腺球蛋白多中心研究组。

Sensitization following Thymoglobulin and Atgam rejection therapy as determined with a rapid enzyme-linked immunosorbent assay. US Thymoglobulin Multi-Center Study Group.

作者信息

Regan J F, Campbell K, Van Smith L, Schroeder T J, Womble D, Kano J, Buelow R

机构信息

SangStat Medical Corporation, Freemont, California 94555, USA.

出版信息

Transpl Immunol. 1999 Jun;7(2):115-21. doi: 10.1016/s0966-3274(99)80028-8.

Abstract

Monoclonal and polyclonal anti-thymocyte preparations play an important role in solid organ transplant immunosuppression. While it is generally accepted that blocking anti-idiotypic antibodies can decrease the efficacy of retreatment with mouse monoclonal antibody preparations, sensitization levels and subsequent effects on treatment efficacy are less clear for polyclonal preparations. Serum samples were obtained from 148 patients participating in a multicentre, double-blind randomized phase III trial comparing Atgam (Pharmacia Upjohn, horse anti-thymocyte globulin) with Thymoglobulin (SangStat Medical Corporation, rabbit anti-thymocyte globulin). Recipients of a first or second renal allograft undergoing biopsy proven acute rejection were randomized to treatment with Atgam or Thymoglobulin. Serum samples were analysed for presence of anti-thymoglobulin and anti-Atgam antibodies. Sensitization levels to rabbit IgG in Thymoglobulin-treated patients (68%, n = 54) was similar to sensitization to horse IgG in Atgam-treated patients (78%, n = 54) (two-sided p value = 0.4, Fisher's exact test), although Atgam-treated patients remained sensitized longer (at day 90, 67% anti-horse IgG positive in Atgam treated vs 24% anti-rabbit IgG in Thymoglobulin positive, p = 0.001). No difference was seen in the production of a crossreactive response. Similarly, sensitization had no significant effect on treatment success or failure. For Thymoglobulin-treated patients, the sensitization rate in successfully treated patients was 68%, while inpatients with treatment failures it was 71% (p = not significant, ns). In Atgam-treated patients, the sensitization rate in successfully treated patients was 82%, while in patients with treatment failures it was 67% (p = ns). In conclusion, patients treated with Thymoglobulin and patients treated with Atgam exhibited similar levels of sensitization, presensitization and crossreactive sensitization, although the anti-horse response was longer lasting; neither presensitization nor treatment-induced sensitization appeared to effect treatment efficacy.

摘要

单克隆和多克隆抗胸腺细胞制剂在实体器官移植免疫抑制中发挥着重要作用。虽然人们普遍认为,阻断抗独特型抗体可降低小鼠单克隆抗体制剂再治疗的疗效,但对于多克隆制剂,致敏水平及其对治疗效果的后续影响尚不清楚。从148名参与一项多中心、双盲随机III期试验的患者中获取血清样本,该试验比较了Atgam(法玛西亚普强公司,马抗胸腺细胞球蛋白)和Thymoglobulin(SangStat医疗公司,兔抗胸腺细胞球蛋白)。接受首次或第二次肾移植且经活检证实发生急性排斥反应的受者被随机分配接受Atgam或Thymoglobulin治疗。分析血清样本中抗胸腺球蛋白和抗Atgam抗体的存在情况。Thymoglobulin治疗患者中对兔IgG的致敏水平(68%,n = 54)与Atgam治疗患者中对马IgG的致敏水平(78%,n = 54)相似(双侧p值 = 0.4,Fisher精确检验),尽管Atgam治疗患者致敏持续时间更长(在第90天,Atgam治疗组67%抗马IgG呈阳性,而Thymoglobulin组24%抗兔IgG呈阳性,p = 0.001)。交叉反应性应答的产生未见差异。同样,致敏对治疗成功或失败无显著影响。对于Thymoglobulin治疗的患者,成功治疗患者的致敏率为68%,而治疗失败患者为71%(p = 无显著性差异,ns)。在Atgam治疗的患者中,成功治疗患者的致敏率为82%,而治疗失败患者为67%(p = ns)。总之,接受Thymoglobulin治疗的患者和接受Atgam治疗的患者表现出相似的致敏、预致敏和交叉反应致敏水平,尽管抗马反应持续时间更长;预致敏和治疗诱导的致敏似乎均未影响治疗效果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验